J&J, Flush With Cash, Has Flexibility To Be ‘Bolder’ On M&A, CEO Duato Says

The company kicked off the new year with a new CEO, plans to break out consumer health, and a strong financial position, including $32bn in cash and lowest level of net debt in more than four years.

burning money
J&J said it has money to burn and is interested in spending on deals this year • Source: Alamy

Johnson & Johnson is starting 2022 in a strong financial position with flexibility to act boldly on business development to build out the pharmaceutical portfolio, CEO Joaquin Duato said during the company's fourth quarter sales and earnings call on 25 January. The quarterly call was the first for Duato as chief executive after taking over the role from Alex Gorsky at the start of the year.

"We are about to turn from a net debt to a net cash position for the first time in over...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.